IP Library › Granted Patent US 8,110,547
Granted Patent B2
US 8,110,547 · App. 11/813,700 · Granted Feb 7, 2012

Compositions for buccal delivery of parathyroid hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,110,547
App. No.
11/813,700
Granted
Feb 7, 2012
Kind
B2
Abstract

Compositions and pharmaceutical formulations for buccally delivering parathyroid hormone comprising a) a delivery agent, b) a PTH component and, optionally, c) an antiresorptive agent are provided.

Claims (11)

1. A pharmaceutical composition for administration through the cheek lining comprising (a) a delivery agent selected from 4-MOAC, and pharmaceutically acceptable salts thereof, and (b) a parathyroid hormone component, wherein the composition is free of calcitonin.

2. The composition of claim 1 , wherein the delivery agent is a monosodium salt of 4-MOAC.

3. A method for preventing or treating osteoporosis in a patient in need thereof comprising administering through the cheek lining an effective amount of a pharmaceutical composition comprising (a) a delivery agent selected from 5-CNAC, 4-MOAC, and pharmaceutically acceptable salts thereof, and (b) a parathyroid hormone component, wherein the composition is free of calcitonin.

4. A method of stimulating new bone formation in a patient comprising administering through the cheek lining an effective amount of a pharmaceutical composition comprising (a) a delivery agent selected from 5-CNAC, 4-MOAC, and pharmaceutically acceptable salts thereof, and (b) a parathyroid hormone component, wherein the composition is free of calcitonin.

5. A method for treating hypoparathyroidism in a patient in need thereof comprising administering through the cheek lining an effective amount of a pharmaceutical composition comprising (a) a delivery agent selected from 5-CNAC, 4-MOAC, and pharmaceutically acceptable salts thereof, and (b) a parathyroid hormone component, wherein the composition is free of calcitonin.

6. The method of claim 3 , wherein the delivery agent is 5-CNAC, or a pharmaceutically acceptable salt thereof.

7. The method of claim 4 , wherein the delivery agent is 5-CNAC, or a pharmaceutically acceptable salt thereof.

8. The method of claim 5 , wherein the delivery agent is 5-CNAC, or a pharmaceutically acceptable salt thereof.

9. The method of claim 6 , wherein the delivery agent is a monosodium salt of 5-CNAC.

10. The method of claim 7 , wherein the delivery agent is a monosodium salt of 5-CNAC.

11. The method of claim 8 , wherein the delivery agent is a monosodium salt of 5-CNAC.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2007
From: LEE, JONGBIN; LIU, PUCHUN; DINH, STEVEN
To: EMISPHERE TECHNOLOGIES
Reel/Frame 019661/0923 →